- Home
- A-Z Publications
- Letters in Drug Design & Discovery
- Previous Issues
- Volume 21, Issue 13, 2024
Letters in Drug Design & Discovery - Volume 21, Issue 13, 2024
Volume 21, Issue 13, 2024
-
-
Targets and Mechanisms of Resveratrol against Endothelial-Mesenchymal Transition in Atherosclerosis: A Network Pharmacology Analysis Combined with In vivo Experiments
Authors: Xin Gao, Xiao-Juan Man, Bo He, Juan Xiang and Jin-Song ChenBackgroundAtherosclerosis (AS) is a chronic inflammatory disease characterized by plaque formation and endothelial dysfunction. Under pro-inflammatory conditions, the endothelial-mesenchymal transition (EndMT) plays an important role in the pathogenesis of AS. Resveratrol (RES) is a natural polyphenol in traditional Chinese medicines, which has been proven to possess anti-AS effects. However, the mechanism of RES Read More
-
-
-
Morphine-like Novel Compounds for the Treatment of Depressive Symptoms
Authors: Diksha Choudhary, Rajwinder Kaur and Bhupinder KumarDepression is a severe mental disorder characterized by a major imbalance between the levels of neurotransmitters. US11534436 B2 discloses an efficient amount of µ-opioid receptor agonists or their pharmaceutically acceptable salt for efficient treatment of depression. The patent discloses a few new compounds among which compounds 1, 2, 3, 4, and 5 as well as derivatives of basic nucleus A have good µ-opioid receptor ag Read More
-
Volumes & issues
-
Volume 21 (2024)
-
Volume 20 (2023)
-
Volume 19 (2022)
-
Volume 18 (2021)
-
Volume 17 (2020)
-
Volume 16 (2019)
-
Volume 15 (2018)
-
Volume 14 (2017)
-
Volume 13 (2016)
-
Volume 12 (2015)
-
Volume 11 (2014)
-
Volume 10 (2013)
-
Volume 9 (2012)
-
Volume 8 (2011)
-
Volume 7 (2010)
-
Volume 6 (2009)
-
Volume 5 (2008)
-
Volume 4 (2007)
-
Volume 3 (2006)
-
Volume 2 (2005)
-
Volume 1 (2004)
Most Read This Month
Article
content/journals/lddd
Journal
10
5
false
en
